Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Journal of Clinical Pharmacology|July 20, 2005
Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministrationBrian P Kearney, Srinivasan Ramanathan, Andrew K Cheng, et al.Antiviral Therapy|April 28, 2006
Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adultsMatthew Law, Rebekah Puls, Andrew K Cheng, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 3, 2006
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavirBrian P Kearney, Anita Mathias, Angelique Mittan, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 1, 2009
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934Nicolas A Margot, Jeff Enejosa, Andrew K Cheng, et al.AIDS (London, England)|June 5, 2002
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DFNicolas A Margot, Erica Isaacson, Ian McGowan, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarateDamian J McColl, Nicolas A Margot, Michael Wulfsohn, et al.Journal of Clinical Pharmacology|November 18, 2005
Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosineBrian P Kearney, John R Sayre, John F Flaherty, et al.Antiviral Therapy|October 17, 2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patientsKirsten L White, Rima Kulkarni, Damian J McColl, et al.HIV Clinical Trials|July 11, 2007
The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patientsIsabel Cassetti, José Valdez R Madruga, Jamal Muhamad A H Suleiman, et al.Pageof 4